Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

IDH1-VAC (IDH1 R132H Peptide Vaccine)

Stage Phase 2

Sponsor German Cancer Research Center

Route subcutaneous

Modality vaccine

Class peptide vaccine

Mechanism long peptide vaccine against the IDH1 R132H neoepitope

Target IDH1 R132H neoepitope (vaccine)

Sources

publication, as of 2026-11-07

https://www.nature.com/articles/s41586-021-03363-z

Platten M et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma (NOA-16, NCT02454634). Nature 2021;592:463-468 (abstract via search record)

Brief source I13

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT02454634

Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine - a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA-16)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07888647

IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas - a Randomized Double-blind Phase 2 Study

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07877415

A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NOA-16

Registry NCT02454634

Phase Phase 1

Status Completed

Enrollment 39

Start 2015-06

Primary completion 2017-09-19

Study completion 2017-09-19

IDH1-vac

Dose not stated in source

Population newly diagnosed IDH1 R132H astrocytoma

Estimand Single arm

vaccine-induced immune response: 93.3%, 28 of 30 evaluable

3-year PFS rate: 63%

STAR-VACC

Registry NCT07888647

Phase Phase 2

Status Not yet recruiting

Enrollment 216

Start 2027-02-01

Primary completion 2034-02-01

Study completion 2035-02-01

Catalyst Primary completion. 02.01.2034. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

iVOCAL

Registry NCT07877415

Phase Phase 1

Status Not yet recruiting

Enrollment 45

Start 2027-01-01

Primary completion 2032-12-31

Study completion 2033-12-31

Catalyst Primary completion. 12.31.2032. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.